Symptom controlNo. of participants: 1814(3 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Overall brain controlNo. of participants: 203(2 RCTs) · patients with newly diagnosed multiple brain metastases
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Neurological function improvement: lower‐dose WBRT vs control dose WBRT (3000 cGy/10 fractions)No. of participants: 1612(5 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules probably leads to higher neurological function improvement: lower‐dose WBRT vs control dose… compared with WBRT control: neurological function improvement (moderate certainty).
1 finding from 1 review
OR 1.74 [1.06, 2.84]
Studies not reported
Moderate
Neurological function improvement: higher‐dose WBRT vs control dose WBRT (3000 cGy/10 fractions)No. of participants: 1480(4 RCTs) · patients with newly diagnosed multiple brain metastases
Altered WBRT fractionation schedules showed no clear difference in neurological function improvement: higher‐dose WBRT vs control dose… compared with WBRT control: neurological function improvement (moderate certainty).
1 finding from 1 review
OR 1.14 [0.92, 1.42]
Studies not reported
Moderate
Overall survivalNo. of participants: 2631(8 RCTs) · patients with newly diagnosed multiple brain metastases
WBRT with radiosensitisers (radiosen) showed no clear difference in overall survivalNo. of participants: 2631(8 RCTs) compared with WBRT alone (moderate certainty).
1 finding from 1 review
HR 1.05 [0.99, 1.12]
Studies not reported
Moderate
Overall survival (survival until death from all causes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in overall survival (survival until death from all causes) compared with laparotomy (moderate certainty).
1 finding from 1 review
Recurrence‐free survival · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in recurrence free survival compared with laparotomy (moderate certainty).
1 finding from 1 review
Serious adverse events (range of outcomes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in serious adverse events (range of outcomes) compared with laparotomy (low certainty).
1 finding from 1 review
Rate of symptom relief · women previously treated for endometrial cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rate of tumour recurrence · women previously treated for endometrial cancer
It is very uncertain whether oestrogen replacement therapy changes rate of tumour recurrence compared with placebo (very low certainty).
1 finding from 1 review
Rate of appearance of a new malignancy · women previously treated for endometrial cancer
It is very uncertain whether oestrogen replacement therapy changes rate of appearance of a new malignancy compared with placebo (very low certainty).
1 finding from 1 review
Rate of survival: overall survival · women previously treated for endometrial cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival (PSF) · women previously treated for endometrial cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Regression rate at 6 months · women with atypical endometrial hyperplasia
It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes regression rate at 6 months compared with medroxyprogesterone (MPA) 10 mg (very low certainty).
1 finding from 1 review
Nausea · women with atypical endometrial hyperplasia
It is very uncertain whether levonorgestrel‐releasing intrauterine system (LNG‐IUS) changes nausea over 6‐month compared with medroxyprogesterone (MPA) 10 mg (very low certainty).
1 finding from 1 review
Vaginal bleeding over 6‐month · women with atypical endometrial hyperplasia
Levonorgestrel‐releasing intrauterine system (LNG‐IUS) may leads to higher vaginal bleeding over 6‐month compared with medroxyprogesterone (MPA) 10 mg (low certainty).
1 finding from 1 review
Maternal blood loss of 500 mL or greater · women undergoing vaginal birth
Direct measurement using calibrated drapes leads to higher blood loss ≥ 500 mL compared with indirect estimation using gravimetric technique (high certainty).
1 finding from 1 review
Blood transfusion · women undergoing vaginal birth
Direct measurement using calibrated drapes showed no clear difference in blood transfusion compared with indirect estimation using gravimetric technique (low certainty).
1 finding from 1 review
Use of plasma expanders · women undergoing vaginal birth
Direct measurement using calibrated drapes showed no clear difference in use of plasma expanders compared with indirect estimation using gravimetric technique (low certainty).
1 finding from 1 review
Use of therapeutic uterotonics · women undergoing vaginal birth
Direct measurement using calibrated drapes showed no clear difference in use of therapeutic uterotonics compared with indirect estimation using gravimetric technique (high certainty).
1 finding from 1 review